PSA Response Signatures - A Powerful New Prognostic Indicator After Radiation For Prostate Cancer?

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology
Article Date: 10 Jan 2009 - 0:00 PDT

email to a friend   printer friendly   opinions  

UroToday.com - This study suggests that it may be possible to identify, prior to treatment, a large sub-group of men with locally advanced prostate cancer whose treatment outcomes are so satisfactory after radiation alone that neo-adjuvant or adjuvant androgen deprivation need not be considered.

We are working on it!

We are also interested in the potential prognostic value of PRS typing during neo-adjuvant androgen deprivation. We will learn more about this issue from the successor trial to 96.01, known as RADAR . It includes six months neo-adjuvant leuprolide plus radiation in the control arm of this trial.

Experimental arms include an additional year of leuprolide and/or 18 months of zoledronate.

Written by J. W. Denham, MD as part of Beyond the Abstract on UroToday.com

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

• Additional
• References
• Citations